Example of keys assays designed to test novel immune-oncology therapies such as check-point-inhibitors, bispecifics, ADC’s, and cellular therapies:
- CD8 T cell: 2D/ 3D Tumour Killing Assay, Antigen-specific CTL-CEFT (phenotype, proliferation, degranulation), MART-1 specific, CTL-cytotoxicity, T cell exhaustion
- CD4 T cell: polyclonal, MLR, antigen specificity, nTreg suppression assay, iTreg polarisation assay
- Natural Killer Cell: activation, proliferation and killing (KIR/NKG2D/ ADCC), Cytokine Release Assay-predictive toxicity
- Macrophage: ADCP, MDSC, M1/M2, TAM, efferocytosis, phagocytosis, Cytokine Release Assay-predictive toxicity
- Dendritic Cell: Antigen uptake and vaccine delivery, cross presentation, neo-antigen immunogenicity; phenotyping
- Cancer cell: Immunogenic Cell Death, 2D/3D Tumour Killing Assays, on/off target assay, CDC
- Fibroblast: Cancer Associated Fibroblast-multicellular tumour killing assays
- Epithelial Cell: on/off target assay, EMT
- Cellular Therapy: CAR-T (on/off target assay, cellular persistence, exhaustion, immunogenicity, tumorgenicity). NK-CAR, TCR based therapeutic, γδ T cell therapeutics (NKG2D/γδ TcR) killing
